USFDA issues 2 observations for Alkem Labs St Louis facility

Published On 2022-09-17 05:00 GMT   |   Update On 2022-09-17 05:01 GMT
Advertisement

Maharashtra: Alkem Labs has recently announced that the US Food and Drug Administration (USFDA) has issued two observations after a pre-approval inspection at the Company's manufacturing facility located at St. Louis, USA.

The inspection was conducted from 06th September 2022 to 14th September 2022.
"At the end of the inspection, the Company has received Form 483 with two (2) observations. There is no data integrity observation," the company stated in a recent BSE filing.
Advertisement

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

"This Pre-Approval Inspection is part of the routine business operations and the Company shall submit to USFDA within the stipulated timeline, a detailed response to close out the said observations," Alkem added.
Medical Dialogues team had earlier reported that the US Food and Drug Administration (USFDA) had issued Form 483 with 3 observations after an inspection at the Company's St. Louis manufacturing facility.

Alkem Labs is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company was founded by Samprada Singh in 1973. The company's portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O.

Akem has 20 manufacturing facilities at multiple locations in India and the United States of America.

Read also: Alkem Labs gets 1 observation from USFDA for Indore facility

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News